Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 3/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5548799 | 0.84 | DRD2 (0.55) | DRD2KDM4DACACBAAK1 | |
| SCHEMBL5543293 | 0.84 | DRD2 (0.55) | DRD2KDM4DACACBAAK1 | |
| SCHEMBL6154916 | 0.82 | KDM4D (0.47) | DRD2KDM4DTRPV4TRPA1AAK1 | |
| SCHEMBL6153458 | 0.77 | KDM4D (0.49) | DRD2KDM4DTRPA1AAK1EGLN2 | |
| SCHEMBL6153457 | 0.77 | KDM4D (0.49) | DRD2KDM4DTRPA1AAK1EGLN2 | |
| SCHEMBL6155283 | 0.77 | KDM4D (0.49) | DRD2KDM4DTRPA1AAK1EGLN2 | |
| SCHEMBL31752283 | 0.77 | GPR119 (0.58) | TRPV4 | |
| SCHEMBL5543202 | 0.76 | DRD2 (0.54) | DRD2ACACB | |
| SCHEMBL5548352 | 0.76 | DRD2 (0.54) | DRD2ACACB | |
| SCHEMBL5549964 | 0.76 | DRD2 (0.54) | DRD2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | claimed |
| US-7230002-B2 | Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-06-12 | — | — | US | disclosed |
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | DPP4, DPP3, DPP7 | DRD2 3398/4885KDM4D 635/4885TRPV4 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.